0602 Burden of Narcolepsy in Japan: A Nationwide Real-world Database Study from The Perspectives of Direct Medical Cost and Comorbidity
Yuta Kamada,Aya Imanishi,Shih-Wei Chiu,Takuhiro Yamaguchi
DOI: https://doi.org/10.1093/sleep/zsad077.0602
IF: 6.313
2023-05-01
SLEEP
Abstract:Abstract Introduction In Japan, narcolepsy is not currently covered by a medical expense assistance program (e.g., System of Medical Payment for Services and Support for Persons with Disabilities). The people living with narcolepsy in Japan have been speaking up against current situation. However, to the best of our knowledge, reports about economic burden (direct + indirect) and comorbidity are limited in Japan. The study objectives were to reveal the burden of narcolepsy from the perspectives of direct medical cost and comorbidity, and also to compare it to epilepsy as a benchmark, which is covered by the above program. Methods Patients diagnosed with narcolepsy (>1 ICD-10code [G47.4]) were identified from April 2017 to March 2022 using an employment-based health insurance claims data compiled by JMDC Inc. Patients with epilepsy (>2 ICD-10code [G40]) were 1:4 matched for age, sex, insurance status, and observation period. Direct medical cost (including inpatient, outpatient, and medication) and comorbidity were analyzed. The 95% confidence intervals (CI) for differences of two diseases were calculated by bootstrapping (direct medical cost) or conditional logistic regression model (comorbidity). The protocol was approved by the Ethics Review Committee of the Tohoku University Graduate School of Medicine. Results We identified 4,594 patients with narcolepsy (sex; 58.7% males, age; 35.2 ± 12.7 years) and 18,376 patients with epilepsy (sex; 58.7% males, age; 35.8 ± 12.2 years). Overall annual direct medical cost per person was 349,188 JPY (narcolepsy) and 521,495 JPY (epilepsy). The difference was -172,307 JPY (95%CI; -199,793JPY to -146,567 JPY). Sleep apnea syndrome (odds ratio; 7.37, 95% CI; 6.52 to 8.33), ADHD (3.21, 2.86 to 3.61), and obesity (1.51, 1.22 to 1.87) were more prevalent in narcolepsy than in epilepsy, while developmental disorders (0.34, 0.27 to 0.41), fracture (0.78, 0.68 to 0.90), and high blood pressure (0.78, 0.71 to 0.86) were less prevalent. Conclusion This study showed direct medical cost and comorbidity of narcolepsy in Japan, which helps future discussion on the medical expense assistance program for people living with narcolepsy. Further research is needed to show the indirect economic burden to clarify the burden of narcolepsy. Support (if any) Eisai Co., Ltd.
neurosciences,clinical neurology